← Back to Analyst Consensus 
IDYA Buy
IDEAYA Biosciences, Inc.
Current Price —
Implied Upside —
Analysts 20
30-Day Momentum
▲ 2 upgrades / ▼ 0 downgrades / 0 reiterations from 2 firms
Next Earnings
Nov 2, 2026 (7 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 16, 2026 | William Blair | initiate | — → Outperform | — | 48% |
| Oct 14, 2026 | Stifel | initiate | — → Buy | — | 53% |
| Sep 9, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 1, 2026 | Citizens | reiterate | Market Outperform → Market Outperform | — | 47% |
| Aug 5, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 5, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jul 7, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Jul 7, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Jun 12, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jun 2, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| May 7, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Apr 14, 2026 | Goldman Sachs | maintain | Neutral → Neutral | — | 54% |
| Apr 14, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Apr 14, 2026 | RBC Capital | maintain | Outperform → Outperform | — | 55% |
| Apr 14, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 14, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Mar 31, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Feb 19, 2026 | Citigroup | maintain | Buy → Buy | $65 | 54% |
| Feb 18, 2026 | RBC Capital | reiterate | Outperform → Outperform | $49 | 55% |
| Feb 18, 2026 | Guggenheim | reiterate | Buy → Buy | $50 | 52% |
| Feb 18, 2026 | Wedbush | maintain | Outperform → Outperform | $52 | 58% |
| Jan 21, 2026 | RBC Capital | maintain | Outperform → Outperform | $45 | 55% |
| Jan 6, 2026 | Truist Securities | maintain | Buy → Buy | $60 | 54% |
| Nov 24, 2025 | Truist Securities | initiate | — → Buy | $59 | 54% |
| Nov 11, 2025 | Mizuho | maintain | Outperform → Outperform | $46 | 52% |
| Oct 23, 2025 | JP Morgan | maintain | Overweight → Overweight | $79 | 54% |
| Oct 21, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $30 | 54% |
| Oct 21, 2025 | RBC Capital | maintain | Outperform → Outperform | $41 | 55% |
| Oct 21, 2025 | BTIG | reiterate | Buy → Buy | $62 | 52% |
| Sep 18, 2025 | Guggenheim | initiate | — → Buy | $50 | 52% |
| Sep 12, 2025 | Mizuho | maintain | Outperform → Outperform | $44 | 52% |
| Sep 9, 2025 | RBC Capital | maintain | Outperform → Outperform | $38 | 55% |
| Sep 9, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Sep 9, 2025 | Stephens & Co. | reiterate | Overweight → Overweight | $45 | 54% |
| Sep 8, 2025 | JMP Securities | maintain | Market Outperform → Market Outperform | $45 | 53% |
| Sep 4, 2025 | JMP Securities | initiate | — → Market Outperform | $41 | 53% |
| Sep 4, 2025 | Barclays | initiate | — → Overweight | $40 | 53% |
| Sep 3, 2025 | JP Morgan | maintain | Overweight → Overweight | $74 | 54% |
| Jul 28, 2025 | JP Morgan | maintain | Overweight → Overweight | $72 | 54% |
| Jul 22, 2025 | TD Cowen | initiate | — → Buy | $0 | 54% |
| Jul 9, 2025 | RBC Capital | maintain | Outperform → Outperform | $30 | 55% |
| Jun 26, 2025 | Wells Fargo | initiate | — → Overweight | $44 | 54% |
| May 22, 2025 | JP Morgan | maintain | Overweight → Overweight | $66 | 54% |
| Feb 14, 2025 | Stephens & Co. | reiterate | Overweight → Overweight | $50 | 54% |
| Jan 15, 2025 | RBC Capital | reiterate | Outperform → Outperform | $61 | 55% |
| Jan 13, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Dec 17, 2024 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Dec 17, 2024 | Wedbush | reiterate | Outperform → Outperform | $52 | 58% |
| Nov 18, 2024 | Stephens & Co. | initiate | — → Overweight | $51 | 54% |
| Nov 5, 2024 | Leerink Partners | downgrade | Outperform → Market Perform | $27 | 51% |
Price Target Trend
May 4, 2026 Oct 26, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days